Oncomed Pharmaceuticals (OMED) Posts Quarterly Earnings, Misses Estimates By $0.34 EPS

Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) posted its quarterly earnings results on Thursday. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.34, AR Network reports.

Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 2.78% on Friday, hitting $22.00. 25,112 shares of the company’s stock traded hands. Oncomed Pharmaceuticals has a 52-week low of $12.07 and a 52-week high of $42.34. The stock’s 50-day moving average is $27.95 and its 200-day moving average is $27.06. The company’s market cap is $648.6 million.

Several analysts have recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Oncomed Pharmaceuticals from $50.00 to $48.00 in a research note on Friday. On a related note, analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, March 25th. They now have a $31.60 price target on the stock. Finally, analysts at Mizuho initiated coverage on shares of Oncomed Pharmaceuticals in a research note on Monday, February 10th. They set a “buy” rating and a $45.00 price target on the stock. One research analyst has rated the stock with a sell rating and three have given a buy rating to the stock. Oncomed Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $40.92.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Study: Probiotics Recipe Could Help Control Weight
Study: Probiotics Recipe Could Help Control Weight
Companies Paying For Posts on Social Networks
Companies Paying For Posts on Social Networks
Amazon Sees Wider Loss on Spending
Amazon Sees Wider Loss on Spending
Bristol-Myers Tops Forecast Thanks to New Drugs
Bristol-Myers Tops Forecast Thanks to New Drugs
Biogen Idec Sales and Profit Fly Past Projections
Biogen Idec Sales and Profit Fly Past Projections
OneWest Bank to be Acquired by CIT in $3.4 Billion Deal
OneWest Bank to be Acquired by CIT in $3.4 Billion Deal


Leave a Reply

 
© 2006-2014 WKRB News.